We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Avadel Pharmaceuticals PLC | NASDAQ:AVDL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.52 | 2.84% | 18.82 | 18.51 | 19.47 | 19.09 | 17.9137 | 18.63 | 874,897 | 05:00:07 |
By Denny Jacob
Jazz Pharmaceuticals on Thursday said its subsidiary filed a complaint alleging that the Food and Drug Administration's unlawfully approved Avadel Pharmaceuticals' new drug application for Lumryz.
The biopharmaceutical company said in a regulatory filing, which outlined their complaint, that the FDA acted outside of its authority under the Orphan Drug Act. Jazz Pharmaceuticals said its product Xywav had orphan drug exclusivity. It said that the FDA approved Lumryz's new drug application and granted it orphan drug exclusivity based on its own findings that it boosts patient care, and is therefore clinically superior to Xywav and another drug it produces, Xyrem. Both drugs treat cataplexy, or excessive daytime sleepiness, in adults with narcolepsy.
Jazz Pharmaceuticals described Lumryz as an extended-release reformulation of Xyrem.
The Ireland-based company said among the complaint's allegations are that the FDA acted without lawful basis when it determined that the dosing regimen for Lumryz makes a major contribution to patient care.
The complaint was filed in the United States District Court for the District of Columbia.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
June 22, 2023 18:44 ET (22:44 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Avadel Pharmaceuticals Chart |
1 Month Avadel Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions